Prostate cancer

Prostate cancer is the most common cancer in men. Over 7,000 new cases are diagnosed in Austria every year – and the trend is rising. However, thanks to modern screening and diagnostic methods, early detection is increasingly possible and significantly improves the chances of recovery.

Prostate cancer treatment with robot-assisted precision

At the Vienna Private Clinic, patients with prostate cancer benefit from a holistic, interdisciplinary treatment approach. Robot-assisted surgery with the Da Vinci system plays a central role in this.

Thanks to this cutting-edge technology, procedures can be carried out with particular precision and without damaging the tissue. For those affected, this means

Lower risk of incontinence and erectile dysfunction
Significantly shorter recovery times
Less postoperative discomfort
Quick return to everyday life

Each treatment plan is individually coordinated in the interdisciplinary tumor board – based on the latest scientific findings and state-of-the-art diagnostic procedures such as multiparametric MRI, Stockholm3 test and MRI-fused perineal prostate biopsy.

Univ.-Prof. Dr. Georg Schatzl

“The Stockholm3 test improves our ability to detect aggressive prostate carcinomas earlier than conventional PSA tests – and thus enables timely, effective therapies. This not only increases the chances of recovery, but also the quality of life of our patients.”

Innovative early detection with the Stockholm3 test

The Vienna Private Clinic is the first clinic in Austria to offer the innovative Stockholm3 test for the early detection of prostate cancer. The blood test was developed on the basis of around 60,000 patient data and sets a new standard in diagnostics – especially when the classic PSA value does not allow a clear statement to be made.

Stockholm3 not only evaluates the PSA value, but also combines it with other biological and clinical parameters: Five additional protein markers, over 100 genetic risk factors as well as information on age, family history and health status are included in the analysis. This holistic approach enables a significantly more differentiated risk assessment.

The result: Stockholm3 detects aggressive prostate carcinomas earlier and more precisely – and at the same time avoids many unnecessary biopsies. The test therefore represents an important advance in personalized preventive medicine.